Diabetic Macular Edema

Ophthalmology·MeSH: Diabetic Retinopathy

Prevalence

81.8 / 100K

25 drugs in development·19 companies·15 clinical trials

Drug Pipeline by Phase

Approved(3)

Drug	Company
ILUVIEN	ANI PHARMACEUTICALS INC (ANIP)
ozurdex	AbbVie Inc. (ABBV)
vabysmo	XOMA Royalty Corporation (XOMA)

Phase 3(7)

Drug	Company
4D-150	4D Molecular Therapeutics, Inc. (FDMT)
4D-150 IVT	4D Molecular Therapeutics, Inc. (FDMT)
avt29	Alvotech (ALVO)
eylea hd	Alvotech (ALVO)
m710	MOMENTA PHARMACEUTICALS INC (MNTA)
opt-302	Opthea Ltd (OPTEY)
Pemetrexed Disodium for Injection	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 2(4)

Phase 1(3)

Drug	Company
ARVN011	Clearside Biomedical, Inc. (CLSDQ)
Avoralstat	BIOCRYST PHARMACEUTICALS INC (BCRX)
ocu200	Ocugen, Inc. (OCGN)

Preclinical(2)

Drug	Company
acu-6151	KUBOTA PHARMACEUTICAL HOLDINGS CO LTD (ACUC)
szn-8141	Surrozen Inc. (SRZN)

Phase 4(6)

Drug	Company
brolucizumab	Novartis AG (NVS)
brolucizumab	NOVARTIS AG (NVSEF)
chloroprocaine ophthalmic gel 3%	HARROW, INC. (IMMY)
Dapagliflozin along with standard medical therapy	ENANTA PHARMACEUTICALS INC (ENTA)
fluorometholone acetate ophthalmic suspension 0.1%	HARROW, INC. (IMMY)
proparacaine hydrochloride ophthalmic solution 0.5%	HARROW, INC. (IMMY)

BioSniper tracks 25 drugs in development for Diabetic Macular Edema across 19 companies.

There are 15 clinical trials targeting Diabetic Macular Edema tracked by BioSniper.

The estimated prevalence of Diabetic Macular Edema is approximately 81.8 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.